Infants with upper gut atresia often have impaired intrauterine growth and gut function. IGF-I is important in fetal growth and is contained in amniotic fluid. We therefore wanted to test the hypothesis that IGF-I infused into fetal gut would reverse the effects of an upper gut obstruction on gut structure and growth in fetal sheep.
Introduction
There is good clinical evidence to suggest that swallowing of amniotic fluid is important for fetal growth and that this effect is greatest in late gestation. Babies with upper gut atresias are at high risk of being born small for gestational age (Cozzi & Wilkinson 1969 , Jolleys 1981 , Pierro et al. 1987 . Babies with congenital gut anomalies are also proportionately smaller if they are born at term than if they are born preterm (Gitlin et al. 1972 , Pierro et al. 1987 , Blakelock et al. 1998 .
It has been estimated that the human fetus swallows up to 760 ml amniotic fluid per day in late gestation (Pritchard 1965 , Gitlin et al. 1972 , and the ovine fetus up to 2000 ml per day (Harding et al. 1984 , Tomoda et al. 1985 . Amniotic fluid contains proteins, carbohydrates and growth factors such as insulin-like growth factor-I (IGF-I) and epidermal growth factor (EGF) (Schindler 1982 , Merimee et al. 1984 , Weaver et al. 1990 ). These nutrients and growth factors can be taken up and utilised by the fetal gut (Lev & Orlic 1972 , Pitkin & Reynolds 1975 , Charlton Char & Rudolph 1979 , Weaver et al. 1990 , Phillips et al. 1991 . Up to 0·3 g/kg or 18% human fetal protein requirements can be derived from the swallowing of amniotic fluid (Gitlin et al. 1972) , and up to 10-14% total nutritional requirement of a rabbit fetus (Mulvihill et al. 1985) . Since fetal growth is constrained by placental factors in late gestation (Gluckman et al. 1990 ) when fetal swallowing is maximal, fetal ingestion may be of greatest importance for fetal growth in late gestation and an inability to swallow may cause a significant impairment in growth.
IGF-I plays a dominant role in the endocrine regulation of fetal growth in late gestation. IGF-I is expressed in all fetal tissues (Han et al. 1988) , and IGF-I levels in fetal and umbilical cord blood correlate with birth size (Gluckman & Brinsmead 1976 , Lassarre et al. 1991 . Mice who have had their IGF-I gene deleted are born markedly growth retarded (Liu et al. 1993) . Furthermore, IGF-I infused into fetal sheep has anabolic effects on feto-placental protein and carbohydrate metabolism .
Ligation of the oesophagus in the fetal rabbit results in a significant reduction in birth weight (Mulvihill et al. 1985) . The enteral infusion of either bovine amniotic fluid or EGF reversed this effect (Mulvihill et al. 1986) . We wanted to test the hypothesis that enteral IGF-I swallowed in amniotic fluid is important for fetal growth and gut development in late gestation. We therefore undertook studies in late gestation fetal sheep to determine whether replacement of IGF-I alone into the gut would reverse the effects of an upper gut obstruction.
Materials and Methods

Animals
Eighteen pregnant ewes were surgically prepared at 90 days gestation (term=145 days). Under halothane anaesthesia and aseptic technique the maternal abdominal wall was opened, and via a hysterotomy the fetal head and neck were delivered. In experimental animals the fetal oesophagus was exposed via a longitudinal left neck incision and divided. The proximal oesophagus was fistulated to the skin of the neck so that swallowed fluid would enter the amniotic sac (Trahair et al. 1986) . A polyvinyl catheter was inserted 10 cm into the distal end of the oesophagus and the oesophagus secured around the catheter to prevent fluid leakage. The neck wound was closed around the catheter and the catheter exteriorised to the maternal flank. In sham operated controls the fetal oesophagus was exposed but not divided. Two amniotic fluid catheters were also placed in each animal and exteriorised to the maternal flank.
Four animals underwent a second operation at 125 days. At this time polyvinyl vascular catheters were placed in the fetal femoral artery and vein via the tarsal vessels and in the fetal common umbilical vein. The fetal portal vein was catheterised via a mesenteric vein and the right and left hepatic veins were catheterised via the inferior vena cava (Bristow et al. 1981) . Catheters were also placed in the maternal uterine vein and maternal carotid and jugular and femoral artery and vein. The catheters placed in the umbilical, portal, hepatic and uterine veins were tipped with silicone tubing to reduce the risk of perforation of these thin walled vessels.
The ewes were housed in individual cages with free access to water and a standard laboratory diet of hay, chopped alfalfa and concentrates. At the end of the experiment the ewes were killed with an overdose of phenobarbitone. The uterus was removed intact from the ewe and the fetal fluids collected and weighed. The position of the catheters was checked and the fetus and placenta were dissected and weighed. The entire bowel from proximal oesophagus to anus was removed, dissected free of its mesenteric attachments and its length measured. Enteric contents were removed and the entire gut was weighed. The uterus was dissected and placentomes individually removed and weighed.
The experiment was approved by the institutional Animal Ethics Committee.
Experimental design
There were three groups of animals; a sham operated control group (sham group, n=6), an oesophageal ligation group in which fetuses were enterally infused with normal saline at 1 ml/h (saline group, n=6) and an oesophageal ligation group in which fetuses were enterally infused with IGF-I at a constant rate of 1 ml/h (IGF-I group, n=6). The concentration of IGF-I was increased at weekly intervals so that the total amount infused increased by 1 µg/day each week from 2 µg/day beginning at 90 days gestation to 8 µg/day beginning at 132 days gestation. Treatment began the day after surgery and continued until the animals were killed at 137 days gestation.
Amniotic fluid samples were collected from all animals every 5 days. At post mortem, blood was collected from ewes and their fetuses. In addition, in the animals which had undergone the second surgery to insert vascular catheters, blood samples were collected simultaneously from the fetal artery, umbilical vein, portal vein, maternal artery and uterine vein on days 7 and 9 after surgery (132 and 134 days gestation). After centrifugation at 4 C, the plasma and amniotic fluid were frozen at 20 C until assayed for IGF-I.
IGF-I concentrations were measured by double antibody radioimmunoassay employing the methodology of Blum & Breier (1994) for the functional separation of IGF-I from IGF-binding proteins (IGFBPs). This IGFBPblocked IGF-I assay uses the high affinity and high specificity of the IGF-I antserum #878/4 (Breier et al. 1991 ) and the addition of excess IGF-II to abolish interference of IGFBPs. Details of the methods and validation are published elsewhere (Blum & Breier 1994) . The minimal detectable dose was 0·02 ng/tube. The intra-and interassay coefficients of variation were 4·2 and 6·8% respectively. Parallelism was observed for all samples between serial dilutions of plasma and amniotic fluid and the standard curve. Recoveries of rhIGF-I added before assay were 95 8% for plasma (mean .., n=10) and 86 9% (n=21) for ovine amniotic fluid. IGF-I values are expressed in terms of international reference IGF-I (IRR IGF-I) (Breier et al. 1991) .
From each fetus three sections of gut were processed for light microscopy. These included duodenum, proximal jejunum (5 cm from ligament of Trietz) and distal ileum (10 cm from ileo-caecal valve). Specimens were fixed in buffered formalin and then embedded in paraffin wax. Sections 4 µm thick were cut at right angles to the long axis and stained with haematoxylin and eosin. Measurements were taken of the muscularis externa, submucosa, mucosa (excluding the villi) and villus length. From these total bowel wall thickness with and without inclusion of the villus length was calculated. All measurements were made using a Leica light microscope with a JVC TK-1281 video attachment connected to a computer with the Mocha Image Analyser program ( Jandel Scientific, Corte Madera, CA, USA). Six measurements of each section were taken and the mean was used for analysis. Villus length was calculated by taking the mean of the longest six villi.
Data analysis
All values are presented as the mean ... The three groups were compared using analysis of variance with Fisher's correction for multiple comparisons. Because we were concerned that fetal growth could be affected by the second surgery, and the numbers of animals which underwent the second surgery differed between experimental groups, the four animals which underwent the second surgery were excluded from analysis of fetal weights and measurements.
Results
Oesophageal ligation (saline group) tended to reduce fetal body and organ weights compared with sham operated controls, although only the reduction in bowel weight and length reached statistical significance (Tables 1 and 2). IGF-I treatment prevented this reduction, so that the IGF-I group were significantly heavier, longer and had greater chest circumference than the saline group at post mortem (Table 1) . They also had greater heart, spleen and thyroid weights than the saline group (Table 2) , and greater crown-rump length and spleen weight than the sham group. When organ weights were expressed relative to their (heavier) body weights, IGF-I treated fetuses had heavier spleens, but smaller brains (Table 2) . Bowel weight was increased but length reduced relative to body weight. As expected after oesophageal ligation, amniotic fluid volumes were greater in both saline and IGF-I groups than the sham group (Table 1 ). Maternal weights were not different between the three groups (IGF-I 53·9 1·7 kg, saline 52·1 2·1 kg, sham 54·8 4·3 kg).
Histological analysis showed that oesophageal ligation (saline group) tended to decrease bowel wall thickness in all regions of the gut studied, although only the submucosal thickness in the duodenum reached statistical significance (Table 3) . Mucus secreting Brunner glands were markedly diminished or absent in the duodenal submucosa in the saline group (Fig. 1) . IGF-I treatment prevented these changes, so that wall thickness in all three regions of the bowel was not different in the IGF-I group from those of the sham controls (Table 3 , Fig. 1 ).
Due to technical problems two sets of amniotic fluid catheters did not sample (one from each of the sham and IGF-I groups). In the remaining sham operated animals, amniotic fluid IGF-I levels remained constant at approximately 2·4 ng/ml over the gestation range we studied (Table 4 ). There was a trend towards slightly higher amniotic fluid IGF-I levels in the saline group until 120 days gestation, but this did not reach statistical significance (mean 3·4 0·4 ng/ml, P=0·13). In the IGF-I group, amniotic fluid IGF-I levels rose gradually with gestation and were approximately twice that of the other two groups by the end of the experiment. Using the known volume of amniotic fluid, we calculated that the total amount of IGF-I available to the fetus in amniotic fluid at the end of the experiment was 3·5 1·0 µg in the sham group, 10·4 2·3 µg in the saline group and 30·6 16·2 µg in the IGF-I group.
Maternal and fetal plasma IGF-I concentrations did not differ between groups at post mortem (maternal sham 140 21, saline 84 12, IGF-I 118 23 ng/ml, fetal sham 61 7, saline 66 12, IGF-I 66 18 ng/ml). Samples taken from undisturbed animals via vascular catheters were only obtained from two sham and two IGF-I animals. The mean maternal and fetal arterial plasma IGF-I concentrations in these animals were not different from those obtained at post mortem (maternal 145 and 107 ng/ml in the sham group, 167 and 52 ng/ml in the IGF-I group, fetal 49 and 46 ng/ml in the sham group, 55 and 43 ng/ml in the IGF-I group). There were no consistent differences in plasma IGF-I concentrations between samples taken from the different catheters in the same animal. In particular, there was no elevation of plasma IGF-I concentrations in the portal veins of the IGF-I infused fetuses (53 and 32 ng/ml respectively). 
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The four fetuses which had undergone a second operation for insertion of vascular catheters were smaller than those which had not. For this reason data from these four fetuses (two sham and two IGF-I treated) were excluded from the fetal measurement and histological analyses. However, if these results were Significantly different from saline treated oesophageal ligation group, *P<0·05, **P<0·01, ***P<0·001.
included it did not change the direction of any results (Table 5 ).
Discussion
This study shows for the first time that enterally administered IGF-I can stimulate fetal growth. Not only did IGF-I infusion prevent the growth retardation induced by oesophageal ligation, but for almost all somatic and individual organ measurements the trend was for the IGF-I group to be larger than the sham operated controls. The effect was not on fetal skeletal growth, as all fetal length measurements were reduced relative to fetal weight. The most noticeable differences in organ size were for the spleen, heart and gut. The increase in heart weight was proportional to the increase in body weight, but the spleen and gut weights were proportionately greater than body weight. The mechanisms by which IGF-I infusion restored fetal growth are not known. It is conceivable, if swallowed nutrients are important for fetal growth, that enhancement of fetal gut function by the effects of IGF-I on gut mucosal development (see below) would enhance gut nutrient uptake and hence fetal growth. However, in this experiment the oesophageal ligation prevented any amniotic fluid nutrients reaching the fetal gut, and hence the effects on gut development cannot by themselves explain the increase in fetal growth.
It is possible that the intraluminal IGF-I was absorbed and had systemic effects on the fetus. The increase in fetal spleen weight which we observed is consistent with the effects of systemic IGF-I administration to fetal sheep (Lok et al. 1996) , and to postnatal animals (Min et al. 1996) . We did not find an increase in the levels of IGF-I in the plasma of the fetuses in the treated group. However, even if the entire dose of infused IGF-I was absorbed, this would be most unlikely to sufficiently perturb circulating levels to be detectable using our current assays. For this reason we measured portal vein IGF-I concentrations, but in the limited data obtained there was again no evidence of systemic IGF-I absorption.
Other experimental evidence for the uptake of IGF-I from the fetal gut is sparse. In an ovine oesophageal ligation model at 125 days gestation, enterally infused IGF-I in doses of 0·025, 0·25 and 2·5 mg over 3 successive days, and found a significant increase in fetal plasma IGF-I levels. In the same study a band of IGF-Ilike immunoreactivity was present in the apical region of villous enterocytes of the proximal small bowel, suggesting that IGF-I was being taken up by the bowel. It was not known whether it was the same IGF-I which was enterally infused which was appearing in the blood. However, the dose of IGF-I used in those experiments was over 300 times the daily dose our fetuses received.
Previous studies producing oesophageal ligation in the ovine model have not shown somatic growth retardation (Avila & Harding 1991 , Trahair & Harding 1992 , Wintour et al. 1997 ) even when oesophageal ligation was performed as early as 62 days (Trahair & Harding 1995) . One study did show a reduction in individual organ weights (liver and pancreas) (Avila & Harding 1991) . However, in that study the weights of control animals were markedly less than those in our own study. Furthermore, if fetal enteral nutrition is of greatest importance in late gestation, then significant growth retardation may not become apparent until close to term, and may therefore have been missed in previous studies. Certainly in the rabbit oesophageal ligation model (Mulvihill et al. 1985 (Mulvihill et al. , 1986 ) and human babies born with an upper gut atresia there is significant somatic growth retardation (Cozzi & Wilkinson 1969 , Jolleys 1981 , Pierro et al. 1987 .
We found that oesophageal ligation impaired fetal gut development. Individual components of the gut wall were altered in all three regions studied, most strikingly in the duodenum where the submucosa was markedly thinner in the saline group than in the other two groups. This seemed in part to be due to a reduction in the number of mucus secreting Brunner glands. Previous studies with fetal ovine oesophageal ligation have also shown an alteration in thickness for individual components in the bowel wall compared with controls (Trahair et al. 1986 , Avila & Harding 1991 . Intestinal enterocyte migration has also been shown to be delayed in this model (Avila & Harding 1991) . Electron microscopy has shown ultrastructural changes including loss of brush border, abnormal cell lysis and cell loss, abnormal lysosomes, and an overall hypomaturity (Trahair & Harding 1992) . These effects were most pronounced in the proximal regions of the small intestine. These findings suggest that the fetal bowel requires the presence of swallowed fluid to grow and function normally. The histological changes almost certainly contribute to the gut dysfunction seen after repair of an upper gut atresia in humans, and the often prolonged dependence on total parenteral nutrition.
IGF-I is known to have trophic effects on neonatal and postnatal gut. It stimulates gut epithelial cell proliferation (Chen et al. 1991 , Steeb et al. 1994 and increases gut weight in rats after dexamethasone treatment or partial gut resection . It may also accelerate maturation of gut permeability (McRoberts & Riley 1992) and brush border enzyme maturation in neonatal rats (Young et al. 1990 , Ma & Xu 1997 . Consistent with these findings, we found that IGF-I infusion increased wall thickness in all regions of the gut studied. We also found considerable variation in villus length within a section of gut examined and between fetuses in the same group. The accuracy of villus measurement with light microscopy has been questioned because the light microscope can only measure in one plane (Touloukian & Wright 1973) , and findings may not correspond with those seen on scanning electron microscopy (Touloukian 1978) . For this reason, we expressed gut wall thickness excluding villus length in our analyses. This is the first report of amniotic fluid IGF-I levels in late gestation in normal sheep, and in an oesophageal ligation model. The relatively constant levels throughout the study period in the sham animals is consistent with observations in human pregnancy (Merimee et al. 1984) , while others have reported a fall in IGF-I levels in late gestation (Kubota et al. 1991 , Bona et al. 1994 ). Past problems with radioimmunoassays for IGF-I affected by the presence of IGFBPs, which are present in large amounts in amniotic fluid (Wang et al. 1990) , may limit interpretation of some of these studies. We therefore used an IGFBP blocked radioimmunoassay using a first antibody with high affinity and specificity for IGF-I, thus allowing excess IGF-II added to the assay to eliminate interference of IGFBPs.
In the saline group the tendency for amniotic fluid IGF-I levels to be slightly higher than in the sham group early in the experiment supports the contention that fetal swallowing may normally make some contribution to mechanisms for clearing IGF-I from the amniotic fluid. Certainly, it has been estimated that up to two thirds of amniotic fluid protein is cleared daily by fetal swallowing (Gitlin et al. 1972) . The apparent fall in amniotic fluid IGF-I levels after 120 days gestation may in part reflect a dilution effect as the volume of amniotic fluid increased in this group.
Amniotic fluid IGF-I levels in the IGF-I infused group rose throughout the study period to reach levels approximately twice those seen in the sham animals. With the accompanying increase in amniotic fluid volume, this resulted in a total amniotic fluid IGF-I content approximately 10-fold higher than that of the sham operated control animals. IGF-I enters amniotic fluid from oral and pulmonary secretions (Spencer et al. 1983 , Hill et al. 1984 , and from fetal urine. Since failure of clearance by swallowing is likely to apply equally to the saline and IGF-I groups in this experiment, the higher amniotic fluid levels in the IGF-I group suggests increased IGF-I concentrations in fluids entering the amniotic sac. Given the propensity of the neonatal gut to allow absorption of whole proteins (Lecce & Broughton 1973 , Werhahn et al. 1981 , including EGF (Thornburg et al. 1984 , Opleta et al. 1987 and IGF-I (Phillips et al. 1995) , it is at least theoretically possible that the infused IGF-I is absorbed by the fetal gut and excreted in the fetal urine. However, it is also possible that the infused IGF-I is acting indirectly, via an unknown second messenger of gastrointestinal origin, to increase IGF-I production in fetal oral, pulmonary or urinary secretions, placenta or membranes, and hence to increase amniotic fluid IGF-I concentrations. In this regard, the effects of IGF-I administration on the levels of IGF-II and the IGFBPs would be of considerable interest in future studies.
Our experiment was designed to infuse IGF-I in physiological amounts approximately equivalent to that normally swallowed. Assuming amniotic fluid IGF-I concentrations of 2·5 ng/ml and fetal swallowing rate increasing from 200 ml/day at 90 days to 800 ml/day in late gestation (Harding et al. 1984 , Tomoda et al. 1985 , this would equate to the fetus swallowing IGF-I from amniotic fluid at a rate of 0·5 µg/day at 90 days increasing to 2 µg/day at term. However, swallowed fluid not only consists of amniotic fluid but also of pulmonary fluid and naso-oral secretions, both of which contain high levels of IGF-I (Schindler 1982 , Hill et al. 1984 . It has been calculated that 18% swallowed fluid is derived from the fetal ovine lungs (Brace et al. 1994) . Thus, it is likely that the fetus normally swallows larger amounts of IGF-I than the above estimate would suggest and that the amounts we infused are of similar magnitude.
Amniotic fluid volume was increased in both oesophageal ligation groups. This is the first report of a consistent finding of polyhydramnios after chronic oesophageal ligation. This is comparable to the finding of polyhydramnios in the majority of human pregnancies where the fetus has a oesophageal atresia without a tracheoesophageal fistula (Beasley 1991) . Some authors have disputed the role of fetal swallowing in the genesis of polyhydramnios, but their conclusions have been based on very limited studies over relatively short periods (Minei & Suzuki 1976 , Wintour & Shandley 1993 . Experimental oesophageal ligation has been reported to increase amniotic fluid volume in some (Fujino et al. 1991 ), but not all, studies (Trahair & Harding 1995) . Our finding that amniotic fluid volume was greater than 2 l (mean 5 l) in 10 of the 12 fetuses with oesophageal ligation lends support to the thesis that failure of fetal swallowing can be the cause of polyhydramnios.
We have shown that small, physiological amounts of IGF-I infused into the fetal gut can enhance fetal growth and gut development. Access to the amniotic fluid is technically far easier than access to the fetus in human pregnancy. Thus, although the mechanisms of action of intraluminal IGF-I are not clear, our observations raise the exciting possibility that IGF-I administered into amniotic fluid and swallowed by the fetus may provide a therapeutic approach to the growth retarded fetus.
